<DOC>
	<DOCNO>NCT00819572</DOCNO>
	<brief_summary>The purpose study determine whether intra-articular injection DLX105 knee joint patient suffer severly painful osteoarthritis safe reduces pain .</brief_summary>
	<brief_title>Study Intra-articular DLX105 Applied Patients With Severely Painful Osteoarthritis Knee</brief_title>
	<detailed_description>Treatment option patient suffer osteoarthritis remain limited . TNF-alpha identified major pro-inflammatory component induce perpetuate peripheral hyperalgesia cartilage degeneration various preclinical study . DLX105 antibody fragment comparably low molecular weight , associate exceptional local biodistribution pattern upon intra-articular injection . In addition , due short systemic half life compare conventional monoclonal antibody , systemic exposure DLX105 upon intra-articular administration low . This study design determine safety local tolerability profile single intra-articular injection ESBA105 well define DLX105 's effect size effect duration reduce pain patient suffer severely painful osteoarthritis knee . The study conduct two sequential part . In first part , 4 different dos DLX105 compare sequential , escalate scheme placebo treatment total 24 patient . In second part study , two dos DLX105 choose base safety data first part compare placebo treatment total 102 patient .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Immunoglobulin Fragments</mesh_term>
	<criteria>Body mass index &lt; 30 . Patients diagnose OA knee ( unilateral bilateral ) accord American College Rheumatology ( ACR ) Criteria classification idiopathic OA ( clinical radiological criterion ) knee Screening ( ACR criterion , see Appendix 16.1 ) . Radiographic evidence tibiofemoral OA within last 6 month Screening , consist Grade II Grade III change , accord KellgrenLawrence grading system . Presence pain index knee ( case bilateral OA , `` index knee '' painful knee ) define level ≥ 60 mm 100 mm ( linear ) VAS Screening . Paracetamol NSAIDs ( apart acetyl salicylic acid ≤ 100 mg/day ) must withdraw least 24 hour prior Screening . Doses `` chondroprotective '' agent contain glucosamine and/or chondroitin sulphate must stable least 3 month prior Screening . Doses nonprescription medication claim effect sign symptom OA must stable least 3 month prior Screening . Use nonpharmacological treatment modality must stable least 3 month prior Screening . Negative QuantiFERONTB Gold test . Radiographic evidence tibiofemoral OA within last 6 month Screening , consist Grade IV , accord KellgrenLawrence grading system . Instability index knee joint &gt; 10° assess goniometer Screening . Arthroscopic open surgery index knee joint within 6 month prior Screening . Posttraumatic secondary OA knee . Isolated OA patellofemoral joint . Comorbidity would confound measurement knee pain Evidence inflammatory arthritis . History Reiter 's Syndrome , RA , psoriatic arthritis , ankylose spondylitis , lymphoma , arthritis associate inflammatory bowel disease , sarcoidosis , amyloidosis , inflammatory disease ( immune mediate inflammatory disease ) may affect knee . Local systemic contraindication i.a . injection Screening Baseline . Any i.a . injection ( corticosteroid , hyaluronic acid , etc . ) within 3 month prior Screening . History high risk exposure Mycobacterium tuberculosis . Human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C infection . Uncontrolled diabetes cardiovascular disease ( New York Heart Association criterion III + IV ) , include uncontrolled hypertension ( &gt; 160/100 mmHg ) . Active infectious episode , history recurrent chronic systemic infection . Malignancy within 5 year prior Screening , except surgicallycured non melanoma skin cancer cervical carcinoma situ . Significant haematological disease within 1 month prior Screening . Moderately severely impaired hepatic function , laboratory value reflect inadequate hepatic function Additional criterion subpopulation patient undergoing MRI : Contraindications MRI . Known allergy gadolinium contrast material . Presence chronic renal failure define calculated creatinine clearance ( CrCl ) &lt; 60 mL/min , use CockcroftGault estimate GFR</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>TNF-alpha</keyword>
	<keyword>DLX105</keyword>
	<keyword>scFv antibody fragment</keyword>
	<keyword>pain</keyword>
	<keyword>fragment</keyword>
	<keyword>antibody fragment</keyword>
</DOC>